GEN Exclusives

More »

GEN News Highlights

More »
Jan 3, 2007

FivePrime and Centocor Partner on Osteoarthritis and Pulmonary Fibrosis Therapeutics

  • Five Prime Therapeutics and Centocor Research and Development will focus on novel therapeutic products to treat osteoarthritis and pulmonary fibrosis, under a worldwide collaborative research and license agreement.

    FivePrime will screen its comprehensive protein library against cell-based assays directed to osteoarthritis and fibrosis. Centocor will have exclusive rights to the proteins and targets identified in these screens.

    FivePrime will receive an upfront payment of $15 million comprised of cash and an equity investment by Johnson and Johnson Development (JJDC) and two years research funding from Centocor. Centocor will have exclusive worldwide rights to develop and commercialize products and targets discovered during the research term in exchange for future milestones and royalties.

    "With Centocor as a partner in these disease areas, we should be able to move the products of our discovery platform into clinical trials faster and more effectively," comments Lewis T. Williams, FivePrime's founder and executive chairman.


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

The Triple Package and Success

One theory for explaining “success," put forward by Amy Chua Jed Rubenfeld, posits cultural traits such as a superiority complex, personal insecurity and impulse control. Union College professors Joshua Hart and Christopher Chabris counter that intelligence, conscientiousness, and economic advantage are the most likely elements of success, regardless of ethnicity. Do you think that Hart-Chabris make a better argument for achieving success than the Chua-Rubenfeld theory?

More »